Funding Update
Mercia Ventures has continued its support into Invizius by leading a £950,000 funding round.
The Edinburgh-based biotech company is developing breakthrough treatments for patients on dialysis and the latest investment will enable the company to prepare for the next stage of clinical trials of its H-Guard product and comes in the run-up to a Series B investment round early next year.
H-Guard addresses the inflammatory responses that patients suffer during dialysis which can cause life-threatening complications including damage to organs and the cardiovascular system.
Mercia Ventures, who has supported Invizius since 2018, was supported by Calculus Capital, Syensqo, The University of Edinburgh's Old College Capital and Scottish Enterprise.
225+ Founders $3.2B RaisedFounder Lodge. 225+ Founders. $3.2B Raised. 8,274 followers. 8,274 followers.
Invizius raised $1,270,710-Congrats Dr Magnus Nicolson MBA FRSM FRSC. Round Investors: Mercia Ventures, Calculus Capital, Syensqo, the University of Edinburgh’s Old College Capital, Scottish Enterprise
Invizius, based in Edinburgh, Scotland, is a biotech company working on breakthrough treatments for dialysis patients. The company recently raised £950k (around $1M+). Dr Magnus Nicolson MBA FRSM FRSC, the company’s CEO, leads the efforts to bring innovative kidney treatments to market. Congratulations!